NCT04588051 is a Phase 2 clinical trial of Cabozantinib in HCC, sponsored by Stephen Chan Lam.

Who is sponsoring NCT04588051?

NCT04588051 is sponsored by Stephen Chan Lam.

What drugs are being tested in NCT04588051?

Interventions in NCT04588051: Cabozantinib.

Is NCT04588051 still recruiting?

NCT04588051 is currently active, enrolled. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT04588051

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib in Hepatocellular Carcinoma

Active, enrolled Phase 2 Last updated 4 March 2026

What this trial tests

Phase 2 trial testing Cabozantinib in HCC in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 November 2020

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Stephen Chan Lam
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 November 2020
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	2 locations across Hong Kong, South Korea

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

HCC — all drugs for HCC →

Sponsor

Stephen Chan Lam — full company profile →

Who can join

18 and older, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There have been lack of clinical studies on the role of drug treatment in patients who develop progressive disease with immune checkpoint inhibitors. Amongst HCC patients who become intolerant or refractory to sorafenib, cabozantinib has been shown by phase III clinical trial (CELESTIAL) to prolong the overall survival of patients, as compared to placebo. It is expected more patients will be treated with immune checkpoint inhibitors in future, hence it is clinically important to study the efficacy and toxicity of cabozantinib after treatment with immune checkpoint inhibitors. Further, both MET activation and upregulation of regulatory T cells are implicated in resistance mechanism to immune checkpoint inhibitors. Immuno-modulatory effects of cabozantinib have been described in vitro and in murine models for several cancers. Moreover, cabozantinib appears to exert its effect on regulatory T cells (Tregs) via the HGF/c-Met pathway, where this receptor signaling cascade mediates multiple immune cell functions. HGF was shown to suppress DC function and in turn induce Tregs (CD4+ CD25+ FoxP3) in a murine central nervous system (CNS) autoimmunity model. HGF cultured monocytes differentiate into monocytic cells that produce soluble factors that favor immune suppressive conditions ideal for tumor progression. Above immunomodulatory effects could enable cabozantinib to reverse the immunosuppressive phenotype in patients after failure with immune checkpoint inhibitors. The starting dose of cabozantinib of 60mg once daily in the current study is chosen in accordance with approved dose by FDA for treatment of advanced HCC

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
Chan SL, Ryoo BY, Mo F, Chan LL, et al · · 2024 · cited 41× · PMID 38570034 · DOI 10.1016/j.jhep.2024.03.033
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY, Chan LL, Chan SL. · · 2022 · cited 37× · PMID 36005172 · DOI 10.3390/curroncol29080434
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Cerreto M, Cardone F, Cerrito L, Stella L, et al · · 2023 · cited 26× · PMID 37887533 · DOI 10.3390/curroncol30100633
Cellular based immunotherapy for primary liver cancer.
Zheng Y, Li Y, Feng J, Li J, et al · · 2021 · cited 24× · PMID 34372912 · DOI 10.1186/s13046-021-02030-5
Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis.
Bang YH, Lee CK, Yoo C, Chon HJ, et al · · 2022 · cited 15× · PMID 35602405 · DOI 10.1177/17588359221097934
Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.
Zarlashat Y, Abbas S, Ghaffar A. · · 2024 · cited 7× · PMID 38893154 · DOI 10.3390/cancers16112034
Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC.
Kwabiah D, Nagati V, Tripathi MK. · · 2025 · cited 3× · PMID 40716510 · DOI 10.1016/j.drudis.2025.104439

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for HCC

Currently open trials in the same condition.

NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting

Other Stephen Chan Lam trials

Trials by the same sponsor.

NCT05873244 — CXD101 in Immunotherapy-related Liver Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04588051 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stephen Chan Lam
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04588051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing